Ultragenyx Pharmaceutical  logo
Ultragenyx Pharmaceutical RARE
$ 24.31 1.8%

Quarterly report 2025-Q3
added 01-24-2026

report update icon

Ultragenyx Pharmaceutical Net Debt 2011-2026 | RARE

Net Debt can be roughly defined as financial liabilities that an entity classifies in the financing section together with the resources available to service those financial liabilities[1]

Net debt is the obligations that remain after deducting all assets and other liabilities from a company or individual. It represents the sum of debts that an organization or person must repay to their creditors or other parties.

Net debt can include various types of obligations such as loans, borrowings, lease liabilities, or credit card payments. It is important to note that net debt does not include current expenses or obligations such as payroll expenses or current bills.

Assessing net debt is an important financial indicator for evaluating the financial position of a company or individual. If net debt significantly exceeds assets, it may indicate financial difficulties and insolvency. In such cases, the company or individual may face difficulties in meeting their obligations and managing their finances.

Net debt can also be used to compare the financial stability of different companies. The lower the net debt relative to assets, the more stable and financially sound they are considered.

Overall, understanding net debt helps evaluate the financial soundness and ability of a company to meet their obligations. It is an important indicator that assists in making decisions about lending, investments, and financial management.

Annual Net Debt Ultragenyx Pharmaceutical

2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011
- - - - - -161 M -93.6 M -24.3 M -7.43 M -86.2 M -10.6 M

All numbers in USD currency

Indicator range from annual reports

Maximum Minimum Average
-7.43 M -161 M -63.9 M

References

  1. Pizzo, M., Moscariello, N., & Vinciguerra, R. (2015). Market Incentives and Regulators' Activity Shaping Financial Information: An Analysis of the Net Debt Disclosure in Italy. International Journal of Business and Management, 10(1), 1.

Net Debt of other stocks in the Biotechnology industry

Issuer Net Debt Price % 24h Market Cap Country
Acer Therapeutics Acer Therapeutics
ACER
-2.08 M - 2.71 % $ 14 M usaUSA
MorphoSys AG MorphoSys AG
MOR
163 M - 2.43 % $ 254 M germanyGermany
Adverum Biotechnologies Adverum Biotechnologies
ADVM
31.1 M - - $ 86.2 M usaUSA
Acasti Pharma Acasti Pharma
ACST
-27.4 M - 4.01 % $ 150 M canadaCanada
I-Mab I-Mab
IMAB
-1.06 B - - $ 866 M chinaChina
Applied Genetic Technologies Corporation Applied Genetic Technologies Corporation
AGTC
-36 M - - $ 26.5 M usaUSA
Aptorum Group Limited Aptorum Group Limited
APM
-2.77 M $ 0.84 2.78 % $ 4.58 M chinaChina
Alexion Pharmaceuticals, Inc. Alexion Pharmaceuticals, Inc.
ALXN
-402 M - - $ 40.3 B usaUSA
Adagene Adagene
ADAG
-71 M $ 2.95 10.3 % $ 166 M chinaChina
Biophytis SA Biophytis SA
BPTS
-4.01 M - -13.47 % $ 169 M franceFrance
AlloVir AlloVir
ALVR
-62.7 M - 4.14 % $ 49.1 M usaUSA
Ampio Pharmaceuticals Ampio Pharmaceuticals
AMPE
-12 M - -11.43 % $ 502 K usaUSA
Midatech Pharma plc Midatech Pharma plc
MTP
-6.17 M - -18.52 % $ 27.3 M britainBritain
Amarin Corporation plc Amarin Corporation plc
AMRN
-189 M $ 15.08 2.24 % $ 6.15 B irlandaIrlanda
EyeGate Pharmaceuticals, Inc. EyeGate Pharmaceuticals, Inc.
EYEG
-824 K - -1.52 % $ 24.7 M usaUSA
Alterity Therapeutics Limited Alterity Therapeutics Limited
ATHE
-34.7 M $ 3.51 -1.68 % $ 8.45 B australiaAustralia
Applied Molecular Transport Applied Molecular Transport
AMTI
-56.5 M - - $ 10.1 M usaUSA
ARCA biopharma ARCA biopharma
ABIO
-60.6 M - 1052.0 % $ 415 M usaUSA
Aptose Biosciences Aptose Biosciences
APTO
-5.53 M - -45.71 % $ 1.2 M canadaCanada
Acorda Therapeutics Acorda Therapeutics
ACOR
114 M - -24.86 % $ 820 K usaUSA
Athira Pharma Athira Pharma
ATHA
-47.2 M - - $ 269 M usaUSA
Akero Therapeutics Akero Therapeutics
AKRO
-340 M - - $ 3.67 B usaUSA
Aeglea BioTherapeutics Aeglea BioTherapeutics
AGLE
-30.2 M - - $ 1.01 B usaUSA
Albireo Pharma Albireo Pharma
ALBO
-239 M - -0.23 % $ 916 M usaUSA
Brickell Biotech Brickell Biotech
BBI
-29.7 M - -5.38 % $ 6.06 M usaUSA
Институт стволовых клеток человека Институт стволовых клеток человека
ISKJ
246 M - - - russiaRussia
Allena Pharmaceuticals Allena Pharmaceuticals
ALNA
-29.5 M - 3.16 % $ 1.9 M usaUSA
Ascendis Pharma A/S Ascendis Pharma A/S
ASND
-195 M $ 222.25 0.1 % $ 5 B danmarkDanmark
Aptinyx Aptinyx
APTX
-33.8 M - -39.0 % $ 4.57 M usaUSA
Aravive Aravive
ARAV
-49.6 M - -13.39 % $ 1.45 M usaUSA
BioNTech SE BioNTech SE
BNTX
-973 M $ 109.88 -0.42 % $ 27.2 B germanyGermany
Arena Pharmaceuticals Arena Pharmaceuticals
ARNA
-25.4 M - -6.81 % $ 3.04 B usaUSA
BeiGene, Ltd. BeiGene, Ltd.
BGNE
-2.44 B - 0.49 % $ 251 B cayman-islandsCayman-islands
Aridis Pharmaceuticals Aridis Pharmaceuticals
ARDS
-3.05 M - 17.91 % $ 11.1 M usaUSA
Burford Capital Limited Burford Capital Limited
BUR
-135 M $ 9.21 2.56 % $ 1.48 B britainBritain
Aeterna Zentaris Aeterna Zentaris
AEZS
-65.1 M - 5.93 % $ 314 M canadaCanada
AgeX Therapeutics AgeX Therapeutics
AGE
12.6 M - -10.17 % $ 12.2 K usaUSA
Athersys Athersys
ATHX
-27.6 M - 3.77 % $ 22.4 M usaUSA
Akouos Akouos
AKUS
-92.9 M - 0.23 % $ 488 M usaUSA
Avenue Therapeutics Avenue Therapeutics
ATXI
-3.13 K - -52.27 % $ 4.45 M usaUSA
Baudax Bio Baudax Bio
BXRX
1.86 M - 0.59 % $ 63 K usaUSA
Cabaletta Bio Cabaletta Bio
CABA
-188 M $ 2.64 7.99 % $ 3.08 M usaUSA
Can-Fite BioPharma Ltd. Can-Fite BioPharma Ltd.
CANF
-3.5 M $ 4.4 2.8 % $ 9.57 B israelIsrael
Calithera Biosciences Calithera Biosciences
CALA
-56.5 M - -10.95 % $ 876 K usaUSA
Autolus Therapeutics plc Autolus Therapeutics plc
AUTL
-187 M $ 1.44 -1.37 % $ 367 M britainBritain
Amneal Pharmaceuticals Amneal Pharmaceuticals
AMRX
2.28 B $ 14.79 1.83 % $ 4.57 B usaUSA
AIkido Pharma AIkido Pharma
AIKI
-1.04 M - 1.93 % $ 17.4 M usaUSA
AVROBIO AVROBIO
AVRO
-76.6 M - 1083.1 % $ 745 M usaUSA
CureVac N.V. CureVac N.V.
CVAC
-783 M - - $ 867 M germanyGermany
Alpine Immune Sciences Alpine Immune Sciences
ALPN
-63.9 M - - $ 2.17 B usaUSA